

PRESS RELEASE APRIL 19th, 2011

PETER ROTHSCHILD ELECTED TO MOBERG DERMA BOARD

On April 18, 2011 was the Annual General Meeting of Moberg Derma AB (publ). In all suggestions the meeting decided in accordance with the proposal.

The meeting decided that as a new member elects Peter Rothschild.

After the annual general meeting, the board has the following composition:

- Mats Pettersson (Chairman)
- Wenche Rolfsen (Vice Chairman)
- Bertil Karlmark
- Torbjörn Koivisto
- Gustaf Lindewald
- Peter Wolpert
- Peter Rothschild

Mr. Rothschild has extensive experience in health care and biotechnology. He is CEO and founder of BioGaia AB (publ). Peter Rothschild is also chairman of the Loft Industries AB and board member of several of BioGaia subsidiaries. Peter Rothschild has also been a member of Diamyd Medical AB and Perlan AB.

For further information, please contact:

Peter Wolpert, President and CEO of Moberg Derma

Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. The portfolio covers projects in the preclinical phase to approved and launched products. The company began operations at the Karolinska Institute in Stockholm in 2006. Moberg Derma is owned by institutional and private investors, Board and management. For further information, please visit: www.mobergderma.se